Żóltakogwiaździak wielopostaciowy: obraz kliniczny, leczenie, rokowanie. Przegląd literatury


Author(s): Anna Mucha-Malecka, Bogdan Gliński, Krzysztof Malecki1, Krzysztof Roszkowski, Marta Urbańska-Gąsiorowska

Pleomorphic xanthoastrocytoma (PXA) is a superficial, circumscribed rare glial tumor with the typical location in the cerebral hemispheres, particularly in the temporal and parietal lobes. Microscopic features include marked cellular pleomorphism, nuclear atypia, increased mitotic index and presence of necrosis. It affects children and young adults, and has a relatively favorable prognosis with ten-years relapse- free survival, and overall survival of 61% and 70% respectively. Surgery remains the mainstay of treatment, the roles of adjuvant irradiation and chemotherapy remains undefined. Radiotherapy with total doses of 30-60 Gy, delivered in the conventional fractionation regimen is recommended after subtotal resection, and in patients who have anaplastic variant of PXA. Extent of resection, the value of mitotic index and presence of necrosis are the recognized factors influencing clinical outcome.

Share this article

+44 7456035580

Editors List

  • Osamu Tanaka

    Osamu Tanaka
    Assistant Professor,
    Department of Radiation Oncology
    Asahi University Hospital
    Gifu city, Gifu, Japan

  • Maher Abdel Fattah Al-Shayeb

    Department of Surgical Sciences, Ajman University, UAE

  • Andrzej Zdziennicki

    Institute of Gynecology and Obstetrics, Medical University of Lodz, I Clinic of Gynecology and Gynecological Oncology (Lodz, Poland)

  • Krzysztof Urbanski

    Head of the Oncology Gynecology Clinic, Oncology Center - Instytut im. Maria Sklodowska Curie, Department in Krakow (Krakow, Poland)

  • Andrzej Szawlowski

    Klinika Nowotworow Gornego Odcinka Uklad Digestii, Oncology Center - Institute (Warsaw, Poland)